🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
1,930

Quick answer

1,930 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 11684626

    Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer

    The Board of Regents of the University of Texas System · Granted Tue Jun 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11685775

    Method of increasing the ratio of effector T cells to regulatory T cells in a tumor by administering to a subject a TGF-beta inhibitor and a PD-1 antibody

    The Regents of the University of California · Granted Tue Jun 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11680067

    Small molecules for the treatment of primary cancer and cancer metastasis

    The Board of Regents of the University of Texas System · Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11679128

    Methods of producing enriched populations of tumor reactive T cells from peripheral blood

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11679113

    Anticancer treatment for uveal melanoma

    The Regents of the University of California · Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11679112

    Cancer treatments using combinations of CDK and ERK inhibitors

    Biomed Valley Discoveries, Inc. · Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11680105

    Antibody fragments for detecting cancer and methods of use

    Regents of the University of Minnesota · Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11679121

    Morpholino oligonucleotides useful in cancer treatment

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11673966

    Monoclonal and humanized antibodies to a cancer glycopeptide

    The Board of Regents of the University of Texas System · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11672794

    Therapeutic targeting of the BAP1 complex in cancer

    Northwestern University · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11672801

    Compositions and methods for treating cancer

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11672774

    Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors

    Kura Oncology, Inc. · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11667718

    Cancer treatment

    VANDA PHARMACEUTICALS INC. · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11667890

    Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion

    Iovance Biotherapeutics, Inc. · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11667900

    Compositions and methods for enhancing macrophage-mediated antibody guided cancer cell or tumor eradication

    The Regents of the University of California · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11660325

    Compositions and methods of targeting cancer stem cells

    The Board of Regents of the University of Texas System · Granted Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11660295

    Glucocorticoid receptor modulators to treat cervical cancer

    Corcept Therapeutics Incorporated · Granted Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11654193

    Cancer treatment combinations

    The Regents of the University of California · Granted Tue May 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11654157

    Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation

    Shuttle Pharmaceuticals, Inc. · Granted Tue May 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11649438

    Methods and compositions for treating cancer

    CRISPR THERAPEUTICS AG · Granted Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11648307

    Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy

    The Board of Regents of the University of Texas System · Granted Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11643656

    Antisense therapies for treating cancer

    The United States Government represented by the Department of Veterans Affairs · Granted Tue May 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11642354

    Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer

    The Board of Regents of the University of Texas System · Granted Tue May 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11642401

    Activation of resident memory T cells for cancer immunotherapy

    Regents of the University of Minnesota · Granted Tue May 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11642331

    Glucocorticoid receptor modulators to treat pancreatic cancer

    Corcept Therapeutics Incorporated · Granted Tue May 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11640848

    Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden

    REGENERON PHARMACEUTICALS, INC. · Granted Tue May 02 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11638704

    Bicyclic compounds and their use in the treatment of cancer

    TEMPEST THERAPEUTICS, INC. · Granted Tue May 02 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11634482

    Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer

    Julius-Maximilians-Universitat Wurzburg · Granted Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11633385

    Combination compositions for treatment of cancer

    RedHill Biopharma Ltd. · Granted Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11629334

    Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood

    THE UNITED STATES OF AMERICA, represented by the Secretary, Department of Health and Human Services · Granted Tue Apr 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11622977

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Tue Apr 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11618888

    Tumor-selective E1A and E1B mutants

    The Regents of the University of California · Granted Tue Apr 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11613754

    Toxic RNAi active seed sequences for killing cancer cells

    Northwestern University · Granted Tue Mar 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11607426

    Method of targeting oncolytic viruses to tumors

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Mar 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11607450

    Smallpox vaccine for cancer treatment

    Calidi Biotherapeutics, Inc. · Granted Tue Mar 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11607464

    Compositions and methods for the treatment and imaging of cancer

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Mar 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11603412

    Antibodies against CDCP1 for the treatment and detection of cancer

    The Regents of the University of California · Granted Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11603376

    Compositions and methods for treating cancer

    The Regents of the University of California · Granted Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11596660

    Methods of treating bladder cancer

    CG ONCOLOGY, INC. · Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11596633

    SHP2 inhibitor compositions and methods for treating cancer

    Revolution Medicines, Inc. · Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11591579

    Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy

    The Board of Regents of the University of Texas System · Granted Tue Feb 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11583526

    Treatment of prostate cancer

    Takeda Pharmaceutical Company Limited · Granted Tue Feb 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11578371

    Biomarkers for predicting tumor response to and toxicity of immunotherapy

    MIRA DX, INC. · Granted Tue Feb 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11572541

    Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer

    Providence Health & Services—Oregon · Granted Tue Feb 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11572413

    Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

    PRECISION BIOLOGICS, INC. · Granted Tue Feb 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11571484

    Compositions that target tumor-associated macrophages and methods of use therefor

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Feb 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11572408

    Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent

    VACCINEX, INC. · Granted Tue Feb 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11571446

    Gut microbiota and treatment of cancer

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Feb 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

1,930 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.